Why the study?
Does concomitant administration of sIPV, DTaP, and MMR impact immunogenicity and safety in healthy infants aged 18 months?
Does concomitant administration of sIPV, DTaP, and MMR impact immunogenicity and safety in healthy infants aged 18 months?
Co-administration of sIPV, DTaP, and MMR vaccines in 18-month-old infants is safe and preserves immunogenicity, potentially reducing administrative costs.
Supports streamlined infant schedules; leaves open confirmation in larger randomized trials.
Co-administration of the sIPV, DTaP, and MMR was safe and did not impact immunogenicity, which would help to mitigate administrative costs and enhance vaccine coverage rates.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: